Fexuprazan, cinitapride given to 29 yr old female with symptoms of cough and vomiting after having spicy meals non responsive to ppi, adivsed endoscopy after 1 week
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
fexuprazan GERD mechanism of action vs PPI 2024
Searching PubMed
fexuprazan potassium competitive acid blocker GERD
Finding Sources
Finding Sources
Reading Article
Reading Article
Searching the Web
cinitapride prokinetic mechanism 5HT4 agonist dopamine antagonist GERD indications
Searching PubMed
cinitapride prokinetic gastroesophageal reflux
Finding Sources
Here is a thorough clinical breakdown of this prescription and scenario:
Clinical Analysis: 29-Year-Old Female with Post-Prandial Cough, Vomiting - PPI Non-Responder
The Clinical Picture
The symptoms - chronic cough and vomiting triggered by spicy meals, non-responsive to PPI - point toward:
- Laryngopharyngeal Reflux (LPR) / Atypical GERD - cough is a classic extra-esophageal manifestation; PPIs have notoriously poor response rates in LPR (~40-50%)
- Functional Dyspepsia with GERD overlap - nausea/vomiting and postprandial symptoms suggest a motility component on top of acid
- GERD with nocturnal acid breakthrough - PPIs fail to suppress nocturnal acid; a P-CAB addresses this gap
The endoscopy after 1 week is advised to rule out erosive esophagitis, Barrett's, peptic ulcer, or other structural pathology before committing to long-term therapy.
Drug 1: Fexuprazan (P-CAB - Potassium-Competitive Acid Blocker)
Mechanism:
Fexuprazan is a novel reversible, potassium-competitive H+/K+-ATPase inhibitor - it blocks the proton pump by competing with K+ ions at the luminal binding site. This differs fundamentally from PPIs:
| Feature | PPI (e.g., omeprazole) | Fexuprazan (P-CAB) |
|---|---|---|
| Activation | Requires acid activation (prodrug) | Active drug directly - no acid needed |
| Onset | Slow (days to full effect) | Rapid (hours) |
| Food timing | Must be taken before meals | Can be taken regardless of meals |
| Nighttime acid | Poor suppression | Sustained - better nocturnal pH control |
| CYP metabolism | CYP2C19 (genetic polymorphism) | CYP3A4 - fewer inter-individual differences |
| Duration of action | Half-life ~1-1.5 hours | Half-life ~7-10 hours |
Why it was chosen here:
- Patient is a PPI non-responder
- Cough is a feature of LPR/atypical GERD - a 2024 RCT (Kim et al., PMID 39115573) showed fexuprazan 40 mg once daily improved hoarseness and troublesome cough faster than esomeprazole in severe LPR cases
- A 2025 RCT (Kang et al., PMID 40299084) showed fexuprazan 40 mg vs esomeprazole 40 mg for GERD-related chronic cough - both improved cough quality of life comparably, confirming fexuprazan as a valid PPI alternative for this specific symptom (74.3% of that study's patients were female, mean age 39 - very similar to this patient)
- Maintains intragastric pH ≥ 4 more effectively than esomeprazole, particularly overnight
Dose: Typically 40 mg once daily (approved in South Korea, China, and some Asian markets; not yet FDA-approved in the US as of 2025)
Drug 2: Cinitapride (Prokinetic Agent)
Mechanism:
Cinitapride is a benzamide prokinetic that acts as:
- 5-HT4 (serotonin) receptor agonist - enhances acetylcholine release in the myenteric plexus, increasing LES tone, gastric emptying, and intestinal peristalsis
- 5-HT3 receptor antagonist - antiemetic effect
- D2 (dopamine) receptor antagonist (weak) - adds to prokinetic effect without the prominent CNS side effects seen with metoclopramide
Why it was chosen here:
- Vomiting and postprandial symptoms suggest a motility disorder component (delayed gastric emptying or impaired LES tone)
- GERD symptoms triggered by spicy meals + vomiting = likely gastroparesis-like delayed emptying keeping acid in contact with the LES longer
- Cinitapride accelerates gastric emptying, reduces postprandial reflux, and addresses nausea/vomiting directly
- Compared to cisapride (its predecessor), cinitapride at 1 mg TID has not been associated with cardiac arrhythmias - safer cardiac profile
- Not associated with significant CNS side effects unlike metoclopramide
- A 2025 real-world Chinese study (PMID 40332271) confirmed cinitapride is effective and well-tolerated in functional dyspepsia with overlapping GERD symptoms
Dose: 1 mg orally three times daily (with meals)
Why the Combination Makes Sense
| Mechanism Targeted | Drug |
|---|---|
| Excess acid secretion (PPI-resistant) | Fexuprazan 40 mg OD |
| Impaired gastric motility / LES dysfunction | Cinitapride 1 mg TID |
| Extra-esophageal reflux cough | Fexuprazan (faster onset, better nocturnal control) |
| Postprandial vomiting / nausea | Cinitapride (5-HT3 antagonism + prokinetic) |
This is a rational dual-mechanism approach: tackle the acid problem from the P-CAB side (which PPIs failed at) while simultaneously improving gastric motility with the prokinetic.
Why the Endoscopy Was Advised
Endoscopy after 1 week serves several purposes in this case:
- Baseline diagnosis before long-term acid suppression potentially masks findings
- Rule out erosive esophagitis (grade LA-A to D) - guides duration of therapy
- Rule out Barrett's esophagus - important in a young patient with chronic symptoms
- Exclude peptic ulcer disease (PUD), which can present with vomiting
- Detect H. pylori (biopsy/CLO test) - relevant since H. pylori can contribute to dyspepsia and PPI failure
- Rule out eosinophilic esophagitis - increasingly common in young females with atypical symptoms
- Confirm or refute structural vs. functional etiology before labeling as refractory GERD
1 week timing allows the current medications to begin working while ensuring the endoscopy is done early enough that findings are not fully suppressed.
Key Points Summary
- Fexuprazan replaces the failed PPI with a superior, rapid-onset, meal-timing-independent acid suppressor that handles nocturnal acid breakthrough and atypical GERD cough
- Cinitapride addresses the motility arm - vomiting, delayed gastric emptying, LES competence - without the CNS risks of metoclopramide
- The combination addresses both the acid and motility components of a likely mixed acid-motility GERD/LPR presentation
- Endoscopy at 1 week is appropriate to establish a structural diagnosis before long-term treatment
Recent Evidence:
- PMID 40299084 - Fexuprazan vs esomeprazole for GERD-related chronic cough (RCT, 2025) - confirms fexuprazan equivalence for PPI in cough management
- PMID 39115573 - Fexuprazan in laryngopharyngeal reflux (RCT, 2024) - shows faster cough and hoarseness improvement with fexuprazan in severe LPR
- PMID 40332271 - Cinitapride in functional dyspepsia with GERD overlap (2025 real-world study) - confirms efficacy and tolerability
This is a shared conversation. Sign in to Orris to start your own chat.